Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 8;81(1):22-25.
doi: 10.1292/jvms.18-0185. Epub 2018 Nov 8.

Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs

Yasutomo Hori  1 , Hiroto Taira  1 , Yuji Nakajima  1 , Yusyun Ishikawa  1 , Yuki Yumoto  1 , Yuya Maekawa  1 , Akiko Oshiro  1
Affiliations

Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs

Yasutomo Hori et al. J Vet Med Sci. .

Abstract

We investigated the effects of an injectable pimobendan solution (0.15 mg/kg) on cardiac function in healthy dogs. Fifteen dogs were divided into placebo, intravenous pimobendan injection, and subcutaneous pimobendan injection groups. In the placebo, the heart rate, systolic and end-diastolic left ventricular pressure (LVPs and LVEDP), and peak positive (max dP/dt) and negative (min dP/dt) first derivatives of the left ventricular pressure did not change for 60 min. After the intravenous pimobendan injection, LVEDP decreased significantly within 5 min, while the max dP/dt increased, and the effects continued until 60 min. In comparison, there were no hemodynamic changes after the subcutaneous pimobendan injection. This study demonstrates that injectable pimobendan induced a rapid inotropic effect and decreased the LVEDP in dogs.

Keywords: canine; heart failure; phosphodiesterase inhibitor; pimobendan; systolic function.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Changes in heart rate, LVPs, and LVEDP with the intravenous administration of pimobendan. Data are shown as the means ± standard deviation. BL, baseline; LVPs, peak systolic LV pressure; LVEDP, end-diastolic LV pressure. *P<0.05 vs. baseline.
Fig. 2.
Fig. 2.
Changes in max dP/dt and min dP/dt with the intravenous administration of pimobendan. Data are shown as the means ± standard deviation. BL, baseline; max dP/dt, the peak positive first derivatives of the LV pressure; min dP/dt, the peak negative first derivatives of the LV pressure. †P<0.01 vs. baseline, ‡P<0.001 vs. baseline.
See this image and copyright information in PMC

References

    1. Asanoi H., Ishizaka S., Kameyama T., Ishise H., Sasayama S.1994. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J. Cardiovasc. Pharmacol. 23: 268–274. doi: 10.1097/00005344-199402000-00014 - DOI - PubMed
    1. Boswood A., Häggström J., Gordon S. G., Wess G., Stepien R. L., Oyama M. A., Keene B. W., Bonagura J., MacDonald K. A., Patteson M., Smith S., Fox P. R., Sanderson K., Woolley R., Szatmári V., Menaut P., Church W. M., O’Sullivan M. L., Jaudon J. P., Kresken J. G., Rush J., Barrett K. A., Rosenthal S. L., Saunders A. B., Ljungvall I., Deinert M., Bomassi E., Estrada A. H., Fernandez Del Palacio M. J., Moise N. S., Abbott J. A., Fujii Y., Spier A., Luethy M. W., Santilli R. A., Uechi M., Tidholm A., Watson P.2016. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study-a randomized clinical trial. J. Vet. Intern. Med. 30: 1765–1779. doi: 10.1111/jvim.14586 - DOI - PMC - PubMed
    1. Fujino K., Sperelakis N., Solaro R. J.1988. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ. Res. 63: 911–922. doi: 10.1161/01.RES.63.5.911 - DOI - PubMed
    1. Hagemeijer F., Roth W., Brand H. J.1989. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. J. Cardiovasc. Pharmacol. 14 Suppl 2: S57–S64. doi: 10.1097/00005344-198908000-00018 - DOI - PubMed
    1. Häggström J., Boswood A., O’Grady M., Jöns O., Smith S., Swift S., Borgarelli M., Gavaghan B., Kresken J. G., Patteson M., Åblad B., Bussadori C. M., Glaus T., Kovačević A., Rapp M., Santilli R. A., Tidholm A., Eriksson A., Belanger M. C., Deinert M., Little C. J., Kvart C., French A., Rønn-Landbo M., Wess G., Eggertsdottir A., Lynne O’Sullivan M., Schneider M., Lombard C. W., Dukes-McEwan J., Willis R., Louvet A., DiFruscia R.2013. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. J. Vet. Intern. Med. 27: 1441–1451. doi: 10.1111/jvim.12181 - DOI - PubMed

Publication types